Trovagene (TROV) Misses Q1 EPS by 7c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/13/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil settles down 2% on weak demand outlook, hefty US crude build
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
Piper Jaffray Cuts Price Target on Trovagene (TROV) Following 1Q Miss
May 11, 2016 8:06 AM EDTPiper Jaffray maintained a Neutral rating on TrovaGene (NASDAQ: TROV), and cut the price target to $5.00 (from $8.00), following the company's 1Q earnings report. Trovagene reported revenue of $120K, well below the Street's ~$280K estimate. Adjusted EPS of ($0.36) was $0.07 below the Street estimate of ($0.29).
Analyst... More
